Skip to main content
SpringerLink
Log in

Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment

  • Original article
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

L-asparaginase (L-asp) remains one of the key components of acute lymphoblastic leukemia therapy. Immune reactions to the drug are associated with its diminished activity. The aim of the study was to determine the level of IgM, IgG and IgE-class anti-L-asp antibodies during the induction and reinduction phases of acute lymphoblastic leukemia therapy and their influence on L-asp activity.

Methods

The study group comprised 65 patients treated for acute lymphoblastic leukemia in one pediatric oncology center. L-asp antibodies were assessed using ELISA at the end of the induction and reinduction phases. L-asp activity was assessed prior to each drug administration by colorimetry.

Results

At the end of the first exposure to L-asp antibodies were detected in 35 patients (54%). In the reinduction phase of the treatment anti-L-asp antibodies were found in 38/55 patients (69%). In the induction phase patients with inadequate L-asp activity had higher IgM concentrations (median 5.88 versus 2.81 μg/mL, p = 0.03). In the reinduction phase IgG and IgM levels correlated inversely with L-asp activity. Patients with L-asp allergy had higher levels of IgG (median 61.6 versus 18.36 μg/mL, p = 0.01), whereas higher IgE levels were noted in the group of patients with inadequate drug activity (median 0.91 versus 0.64 μg/mL, p = 0.03).

Conclusions

Subsequent exposure to L-asp in the treatment of acute lymphoblastic leukemia was associated with the increase of anti-L-asp antibodies in all studied classes. However, the changes observed in specific classes of antibodies were not distinctive for L-asp hypersensitivity or inactivation, suggesting that the mechanism is more complex.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anishkin A., Vanegas JM, Rogers DM, Lorenzi PL, Chan WK, Purwaha P, et al. Catalytic role of the substrate defines specificity of therapeutic l-asparaginase. J Mol Biol 2015;427:2867–85.

    Article  CAS  Google Scholar 

  2. Dubbers A, Wurthwein G, Muller HJ, Schulze-Westhoff P, Winkelhorst M, Kurzknabe E, et al. Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br J Haematol 2000;109:427–9.

    Article  CAS  Google Scholar 

  3. Broome JD. Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells. J Exp Med 1968;127:1055–72.

    Article  CAS  Google Scholar 

  4. Zalewska-Szewczyk B, Andrzejewski W, Bodalski J. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2004;43:600–2.

    Article  Google Scholar 

  5. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26:217–26.

    Article  Google Scholar 

  6. Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012;26:2303–9.

    Article  CAS  Google Scholar 

  7. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002;99:1986–94.

    Article  CAS  Google Scholar 

  8. Willer A, Gerss J, Konig T, Franke D, Kuhnel HJ, Henze G, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood 2011;118:5774–82.

    Article  CAS  Google Scholar 

  9. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525–32.

    Article  CAS  Google Scholar 

  10. Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, Jedrychowska-Danska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007;48:931–6.

    Article  CAS  Google Scholar 

  11. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8:99–104.

    CAS  Google Scholar 

  12. Killander D, Dohlwitz A, Engstedt L, Franzen S, Gahrton G, Gullbring B, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220–8.

    Article  CAS  Google Scholar 

  13. Leach MW, Rottman JB, Hock MB, Finco D, Rojko JL, Beyer JC. Immunogenicity/hypersensitivity of biologics. Toxicol Pathol 2014;42:293–300.

    Article  CAS  Google Scholar 

  14. Hino M, Shimojo N, Ochiai H, Inoue Y, Ando K, Chikaraishi K, et al. Expression of CD203c on basophils as a marker of immunoglobulin E-mediated (L)-asparaginase allergy. Leuk Lymphoma 2014;55:92–6.

    Article  CAS  Google Scholar 

  15. https://doi.org/www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

  16. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group phase 3 trial. Blood 2002;99:2734–9.

    Article  CAS  Google Scholar 

  17. Zalewska-Szewczyk BM-KL, Czogała M, Balwierz W, Szczepański T, Kowalczyk JR, Młynarski W. Therapeutic L-asparaginase activity monitoring — recommendations of Polish Pediatric Leukemia and Lymphoma Study Group of Polish Society of Pediatric Oncology and Hematology. Przegląd Pediatryczny 2016;45:73–9 Article in Polish.

    Google Scholar 

  18. Vrooman LM, Stevenson KE, Supko JG, O’Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013;31:1202–10.

    Article  CAS  Google Scholar 

  19. Tong WH, Pieters R, Kaspers GJ, te Loo DM, Bierings MB, van den Bos C, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014;123:2026–33.

    Article  CAS  Google Scholar 

  20. Soyer OU, Aytac S, Tuncer A, Cetin M, Yetgin S, Sekerel BE. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. J Allergy Clin Immunol 2009;123:895–9.

    Article  CAS  Google Scholar 

  21. Yang L, Panetta JC, Cai X, Yang W, Pei D, Cheng C, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932–9.

    Article  CAS  Google Scholar 

  22. Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2012;119:1658–64.

    Article  CAS  Google Scholar 

  23. Fabry U, Korholz D, Jurgens H, Gobel U, Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-mediated mechanism. Pediatr Res 1985;19:400–8.

    Article  CAS  Google Scholar 

  24. Patel N, Krishnan S, Offman MN, Krol M, Moss CX, Leighton C, et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest 2009;119:1964–73.

    Article  CAS  Google Scholar 

  25. van der Meer LT, Waanders E, Levers M, Venselaar H, Roeleveld D, Boos J, et al. A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. Blood 2014;124:3027–9.

    Article  Google Scholar 

  26. Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, Mlynarski W. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med 2009;9:113–6.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland

    Justyna Walenciak, Szymon Janczar, Wojciech Młynarski & Beata Zalewska-Szewczyk

  2. Laboratory of Immunopathology and Genetics, Medical University of Lodz, Lodz, Poland

    Krystyna Wyka

Authors
  1. Justyna Walenciak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Krystyna Wyka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Szymon Janczar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wojciech Młynarski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Beata Zalewska-Szewczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beata Zalewska-Szewczyk.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walenciak, J., Wyka, K., Janczar, S. et al. Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment. Pharmacol. Rep 71, 311–318 (2019). https://doi.org/10.1016/j.pharep.2018.11.002

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.pharep.2018.11.002

Keywords

Search

Navigation